Shopping Cart
- Remove All
- Your shopping cart is currently empty
H3B-6545 is a selective estrogen receptor covalent antagonist (SERCA) that is orally available. As a novel class of ERα antagonists, H3B-6545 is used in the study of metastatic breast cancers, such as estrogen receptor-positive (ER), human epidermal growth factor receptor 2-negative (HER2-) breast cancer.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $197 | 8-10 weeks | |
5 mg | $492 | 8-10 weeks | |
10 mg | $729 | 8-10 weeks | |
25 mg | $1,130 | 8-10 weeks | |
1 mL x 10 mM (in DMSO) | $618 | 8-10 weeks |
Description | H3B-6545 is a selective estrogen receptor covalent antagonist (SERCA) that is orally available. As a novel class of ERα antagonists, H3B-6545 is used in the study of metastatic breast cancers, such as estrogen receptor-positive (ER), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. |
In vitro | H3B-6545 is a highly selective small molecule that potently antagonizes wild-type and mutant ERα in biochemical and cell-based assays. In vitro comparisons with standard of care and other experimental agents demonstrated increased cellular potency of H3B-6545 under both continuous and washout treatment conditions.[1] |
In vivo | H3B-6545, orally administered once daily, demonstrated potent activity and superior efficacy to fulvestrant in the MCF-7 xenograft model, with maximal antitumor activity at doses >10-fold below the maximum tolerated dose in mice. In addition, H3B-6545 demonstrated superior antitumor activity to tamoxifen and fulvestrant in xenograft models of estrogen receptor-positive breast cancer, including models harboring ERα mutations. In nonclinical safety studies in rats and monkeys, H3B-6545 was well tolerated over a wide dose range and at exposures significantly exceeding those required for efficacy in mouse xenograft models.[1] |
Alias | H3B6545 |
Molecular Weight | 567.58 |
Formula | C30H29F4N5O2 |
Cas No. | 2052130-80-8 |
Relative Density. | 1.286 g/cm3 (Predicted) |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
Solubility Information | DMSO: 80 mg/mL (140.95 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.